- Home
- MNPR
as 07-26-2024 4:00pm EST
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMETTE |
| Market Cap: | 11.3M | IPO Year: | 2019 |
| Target Price: | $2.00 | AVG Volume (30 days): | 59.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $1.73 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Monopar Therapeutics Inc. (MNPR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 18 '24 | Buy | $0.74 | 20,508 | $15,253.85 | 186,132 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 18 '24 | Buy | $0.86 | 12,000 | $10,320.00 | 165,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 13 '24 | Buy | $0.91 | 12,000 | $10,920.00 | 129,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 13 '24 | Buy | $0.93 | 12,000 | $11,175.60 | 141,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 13 '24 | Buy | $0.90 | 12,000 | $10,798.80 | 153,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 3 '24 | Buy | $0.76 | 12,000 | $9,120.00 | 105,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | Jun 3 '24 | Buy | $0.78 | 12,000 | $9,360.00 | 117,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | May 29 '24 | Buy | $0.64 | 12,000 | $7,676.40 | 81,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | May 29 '24 | Buy | $0.64 | 12,000 | $7,731.60 | 93,624 | SEC Form 4 |
| Cittadine Andrew | MNPR | Chief Operating Officer | May 29 '24 | Buy | $0.64 | 12,000 | $7,642.80 | 69,624 | SEC Form 4 |
Latest Monopar Therapeutics Inc. News
MNPR Breaking Stock News: Dive into MNPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
GlobeNewswire
a month ago
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
GlobeNewswire
a month ago
Monopar and NorthStar Amend & Extend Collaboration
GlobeNewswire
2 months ago
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
MT Newswires
2 months ago
Monopar Therapeutics Names Karthik Radhakrishnan as CFO
GlobeNewswire
2 months ago
Monopar Announces CFO Succession
Zacks
2 months ago
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
GlobeNewswire
3 months ago
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Compare MNPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNPR Monopar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.